Expanding Overseas Market
Bukwang Pharmaceutical Co. announced that it has signed a deal with Kalbe International Pte. Ltd. on March 3 to export its self-developed incrementally modified drug for treatment of diabetic neuropathy called “Dexid Tab” to six countries, including the Philippines and Vietnam.
Taking out of the active R-form from the two stereoisomers of thioctic acid, which is the main ingredient of Thioctacid, the treatment of diabetic neuropathy, the Dexid Tab has the same efficacy but higher levels of safety. It is also a new incrementally modified drug that improves the convenience of patients by reducing dosage from existing 600 milligram to 480 milligram, independently developed and released by Bukwang Pharmaceutical in Korea early 2014.
An official from Bukwang Pharmaceutical said, “We are glad to supply the Dexid Tab, which has been available to only Korean patients, to overseas patients with diabetic neuropathy. Each country has a different registration period but we believe that it will be released in six countries, including Southeast Asia, in two to three years. Also, the company expects to post about US$15 million (18.23 billion won) in overseas shipment in the next five years.”
Bukwang Pharmaceutical plans to push into the global markets of medicine and medical supplies, toothpaste and dietary supplement.